Such developments have spurred explosive growth over the past decade in a diverse array of alternative targeted nanodelivery vehicles used as monotherapies or as part of combinatorial regimens[27] for treating AGC; these have been summarized in a number of excellent comprehensive reviews.[9,28,29] Engineered inorganic particle therapies, for instance, have been developed and conjugated with immune components[30–32] for treating HER2+ gastric cancers. This evidence concerns the gene ERBB2 and gastric cancer.